Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MKTP Procedure Satisfactory for Leukoderma Treatment

J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al

The melanocyte-keratinocyte transplantation procedure (MKTP) provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma, according to a recent study. Furthermore, MKTP can maintain repigmentation for at least 72 months. Researchers performed a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014. Repigmentation was assessed by a 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI). They found:

  • 100 patients had MKTP performed at 236 anatomically-based lesions (ABLs); 63 patients with 157 ABLs had long-term data available (12-72 months; median, 24 months).
  • Segmental vitiligo, nonsegmental vitiligo, and physical leukoderma demonstrated improvement in VASI scores: −75.6 ± 24.6%, −59.2 ± 36.6%, and −32.4 ± 33.5%, respectively.
  • In vitiligo, at 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of ABLs, respectively, maintained >75% repigmentation.
  • Skin phototype, age, and anatomic location of ABLs had no significant effect on the outcome of treatment.

Citation:

Silpa-Archa N, Griffith JL, Huggins RH, et al. Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas. [Published online ahead of print May 11, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.01.056.

This Week's Must Reads

Disease Burden of Atopic Dermatitis in the US, J Invest Dermatol; ePub 2018 Oct 30; Chiesa Fuxench, et al

Psoriasis Associated with Sexual Dysfunction, JAMA Dermatol; ePub 2018 Oct 10; Molina-Leyva, et al

Association Between Psoriasis and Suicide Examined, Dermatolog Ther; ePub 2018 Oct 12; Liang, et al

Study: More Than 85% of Surgeons Use Skin Hooks, Dermatolog Surg; ePub 2018 Oct 9; Clark, et al

FDA Approves Hyrimoz for Plaque Psoriasis, Sandoz news release; 2018 Oct 31

Must Reads in Pigmentation Disorders

Use of OTC Lightening Agents Widespread in the US, J Clin Aesthet Dermatol; 2018 Jul; Saade, et al

Anti-Cancer Therapies, Pigmentary Changes Linked, J Am Acad Dermatol; ePub 2017 Sep 14; Dai, Belum, et al

Morphologic CALM Features Help Determine Treatment, JAMA Dermatol; ePub 2017 Aug 30; Belkin, et al

MKTP Procedure Satisfactory for Leukoderma Treatment, J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al

Hyperpigmentation Patients: Less Sunscreen Usage, J Am Acad Dermatol; ePub 2017 Feb 15; Maymone, et al